Gossamer bio announces inducement grant under nasdaq listing rule 5635(c)(4)

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced that the compensation committee of gossamer's board of directors approved the grant, effective january 6, 2025, to three non-executive employees of non-qualified stock option.
GOSS Ratings Summary
GOSS Quant Ranking